Exelixis raises $71.8 million through stock offering

South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.

Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.

Just Posted

SFUSD going back to basics with school lunches made from scratch

Upgraded culinary center could serve as model for expanded in-house food production.

Sliding doors could open up more space on Muni buses

A simple engineering change could soon make Muni’s 900 buses roomier across… Continue reading

City struggles to find alternatives for inmates in seismically unsafe jail

Mayor London Breed has given City Hall a deadline to close down… Continue reading

E-scooter company Skip announces layoffs after losing SF permit

San Francisco-based e-scooter company Skip this week announced pending layoffs for roughly… Continue reading

Juul suspends sale of flavored e-cigarettes

San Francisco-based e-cigarette maker Juul Labs announced Thursday that it is suspending… Continue reading

Most Read